$CDXC
ChromaDex Corp.

2023 Q1 Form 10-K Financial Statement

#000162828023006968 Filed on March 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $22.56M $21.00M $72.05M
YoY Change 30.69% 18.23% 6.82%
Cost Of Revenue $9.038M $8.980M $29.25M
YoY Change 34.35% 30.31% 12.69%
Gross Profit $13.52M $12.02M $42.80M
YoY Change 28.35% 10.56% 3.15%
Gross Profit Margin 59.93% 57.23% 59.4%
Selling, General & Admin $14.29M $12.18M $56.60M
YoY Change -16.83% -19.54% -12.56%
% of Gross Profit 105.73% 101.37% 132.25%
Research & Development $1.193M $1.279M $4.826M
YoY Change 10.67% 22.39% 25.94%
% of Gross Profit 8.83% 10.64% 11.28%
Depreciation & Amortization $228.0K $264.0K $869.0K
YoY Change 13.43% 0.76% -2.36%
% of Gross Profit 1.69% 2.2% 2.03%
Operating Expenses $15.49M $13.46M $61.43M
YoY Change -15.21% -16.83% -10.41%
Operating Profit -$1.968M -$1.444M -$18.63M
YoY Change -74.55% -72.84% -31.19%
Interest Expense $66.00K $26.00K $3.000K
YoY Change 725.0% -388.89% -94.55%
% of Operating Profit
Other Income/Expense, Net $0.00 $2.085M
YoY Change
Pretax Income -$1.902M -$1.418M -$16.54M
YoY Change -75.43% -73.37% -39.03%
Income Tax
% Of Pretax Income
Net Earnings -$1.902M -$1.418M -$16.54M
YoY Change -75.43% -73.37% -39.03%
Net Earnings / Revenue -8.43% -6.75% -22.96%
Basic Earnings Per Share -$0.03 -$0.24
Diluted Earnings Per Share -$0.03 -$0.02 -$0.24
COMMON SHARES
Basic Shares Outstanding 74.84M shares 74.47M shares 69.73M shares
Diluted Shares Outstanding 74.80M shares 69.73M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.99M $20.24M $20.24M
YoY Change 10.56% -28.27% -28.27%
Cash & Equivalents $23.00M $20.30M
Short-Term Investments
Other Short-Term Assets $2.447M $3.167M $3.167M
YoY Change 15.81% 70.36% 70.36%
Inventory $11.91M $14.68M $14.68M
Prepaid Expenses
Receivables $9.221M $8.482M $5.382M
Other Receivables -$3.500M $3.100M $3.100M
Total Short-Term Assets $46.57M $46.57M $46.57M
YoY Change 4.59% -4.78% -4.78%
LONG-TERM ASSETS
Property, Plant & Equipment $6.041M $6.322M $6.322M
YoY Change -13.61% -14.04% -14.04%
Goodwill
YoY Change
Intangibles $630.0K $671.0K
YoY Change -22.03% -21.7%
Long-Term Investments
YoY Change
Other Assets $532.0K $497.0K $497.0K
YoY Change -12.21% -31.26% -31.26%
Total Long-Term Assets $7.203M $7.490M $7.490M
YoY Change -14.32% -16.17% -16.17%
TOTAL ASSETS
Total Short-Term Assets $46.57M $46.57M $46.57M
Total Long-Term Assets $7.203M $7.490M $7.490M
Total Assets $53.77M $54.06M $54.06M
YoY Change 1.58% -6.54% -6.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.951M $9.679M $9.679M
YoY Change -8.48% -7.14% -7.14%
Accrued Expenses $8.610M $7.337M $8.017M
YoY Change 5.96% 13.21% 14.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $17.00K $16.00K $16.00K
YoY Change 0.0% -20.0% -20.0%
Total Short-Term Liabilities $18.42M $17.87M $17.87M
YoY Change -1.45% 1.45% 1.45%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $22.00K $22.00K
YoY Change
Other Long-Term Liabilities $7.308M $7.494M $7.494M
YoY Change -12.57% -11.84% -11.84%
Total Long-Term Liabilities $7.328M $7.516M $7.516M
YoY Change -12.33% -11.58% -11.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.42M $17.87M $17.87M
Total Long-Term Liabilities $7.328M $7.516M $7.516M
Total Liabilities $25.75M $25.39M $25.39M
YoY Change -4.81% -2.79% -2.79%
SHAREHOLDERS EQUITY
Retained Earnings -$187.4M -$185.5M
YoY Change 6.07% 9.79%
Common Stock $74.00K $74.00K
YoY Change 8.82% 8.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.02M $28.67M $28.67M
YoY Change
Total Liabilities & Shareholders Equity $53.77M $54.06M $54.06M
YoY Change 1.58% -6.54% -6.54%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$1.902M -$1.418M -$16.54M
YoY Change -75.43% -73.37% -39.03%
Depreciation, Depletion And Amortization $228.0K $264.0K $869.0K
YoY Change 13.43% 0.76% -2.36%
Cash From Operating Activities $2.800M -$328.0K -$15.10M
YoY Change -138.89% -93.37% -37.51%
INVESTING ACTIVITIES
Capital Expenditures $91.00K $172.0K $334.0K
YoY Change -464.0% -8700.0% -181.66%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$91.00K -$172.0K -$334.0K
YoY Change 264.0% 8500.0% -18.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.747M
YoY Change -71.03%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$1.000K 7.679M $7.654M
YoY Change -66.67% 12088.89% -78.79%
NET CHANGE
Cash From Operating Activities $2.800M -328.0K -$15.10M
Cash From Investing Activities -$91.00K -172.0K -$334.0K
Cash From Financing Activities -$1.000K 7.679M $7.654M
Net Change In Cash $2.700M 7.179M -$7.778M
YoY Change -137.37% -247.02% -167.51%
FREE CASH FLOW
Cash From Operating Activities $2.800M -$328.0K -$15.10M
Capital Expenditures $91.00K $172.0K $334.0K
Free Cash Flow $2.709M -$500.0K -$15.43M
YoY Change -137.76% -89.88% -35.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001386570
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37752
CY2022 dei Entity Registrant Name
EntityRegistrantName
CHROMADEX CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2940963
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
10900 Wilshire Blvd
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
CY2022 dei City Area Code
CityAreaCode
310
CY2022 dei Local Phone Number
LocalPhoneNumber
388-6706
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
CDXC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
79200000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74838491 shares
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
New York, NY
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20441000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28219000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
122000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
65000 usd
CY2022Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
3100000 usd
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2100000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8482000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5226000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
14677000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
13601000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2967000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1859000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
46567000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
48905000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2799000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3003000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
671000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
857000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3523000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4352000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
723000 usd
CY2022Q4 us-gaap Assets
Assets
54057000 usd
CY2021Q4 us-gaap Assets
Assets
57840000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9679000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10423000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7337000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
680000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
16000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
20000 usd
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
157000 usd
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
161000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17869000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17613000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3955000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4346000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3539000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4154000 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
22000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Liabilities
Liabilities
25385000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
26113000 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57840000 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74567000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74567000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68126000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68126000 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
74000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
68000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
214094000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200614000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185493000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168953000 usd
CY2022Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-3000 usd
CY2021Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-2000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
28672000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31727000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54057000 usd
CY2022 us-gaap Advertising Expense
AdvertisingExpense
11400000 usd
CY2022 us-gaap Revenues
Revenues
72050000 usd
CY2021 us-gaap Revenues
Revenues
67449000 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
29253000 usd
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
25959000 usd
CY2022 us-gaap Gross Profit
GrossProfit
42797000 usd
CY2021 us-gaap Gross Profit
GrossProfit
41490000 usd
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28313000 usd
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28352000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4826000 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3832000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28286000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36379000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
61425000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
68563000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-18628000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-27073000 usd
CY2022 cdxc Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2085000 usd
CY2021 cdxc Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
0 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-55000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16540000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69729000 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69729000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67185000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67185000 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16424000 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
400000 usd
CY2021 cdxc Issuance Of Common Stock Net Of Offering Costs Amount
IssuanceOfCommonStockNetOfOfferingCostsAmount
26740000 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9495000 usd
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6195000 usd
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
1000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31727000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
400000 usd
CY2022 cdxc Issuance Of Common Stock Net Of Offering Costs Amount
IssuanceOfCommonStockNetOfOfferingCostsAmount
7747000 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5739000 usd
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
-1000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16540000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
28672000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16540000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 usd
CY2022 us-gaap Depreciation
Depreciation
869000 usd
CY2021 us-gaap Depreciation
Depreciation
890000 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
186000 usd
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
225000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
829000 usd
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
511000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5739000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6195000 usd
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000 usd
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
63000 usd
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
46000 usd
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-67000 usd
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-108000 usd
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3319000 usd
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2578000 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1076000 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1918000 usd
CY2021 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
110000 usd
CY2022 cdxc Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
304000 usd
CY2021 cdxc Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
278000 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
872000 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
810000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-744000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
978000 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
856000 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
348000 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-391000 usd
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-95000 usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5000 usd
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-116000 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-463000 usd
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-541000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15098000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24163000 usd
CY2022 cdxc Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
334000 usd
CY2021 cdxc Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
409000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-334000 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-409000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7747000 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26740000 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9495000 usd
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
77000 usd
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
110000 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16000 usd
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
31000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7654000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36094000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7778000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11522000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28219000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16697000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20441000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28219000 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1000 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
507000 usd
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
541000 usd
CY2022 cdxc Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment
RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment
0 usd
CY2021 cdxc Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment
RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment
3637000 usd
CY2022 cdxc Finance Lease Obligation Incurred For Purchase Of Computer Equipment And Software
FinanceLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware
34000 usd
CY2021 cdxc Finance Lease Obligation Incurred For Purchase Of Computer Equipment And Software
FinanceLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware
0 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
Nature of BusinessChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex International, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, Asia Pacific Scientific, Inc., ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex” or the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors.ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen®. The Company further develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. Additionally, the Company offers natural product fine chemicals, known as phytochemicals, and related research and development services.
CY2022 us-gaap Use Of Estimates
UseOfEstimates
Use of Accounting Estimates: The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4300000 usd
CY2022 cdxc Shipping And Handling Fees
ShippingAndHandlingFees
428000 usd
CY2021 cdxc Shipping And Handling Fees
ShippingAndHandlingFees
336000 usd
CY2021 us-gaap Advertising Expense
AdvertisingExpense
12500000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents and trade receivables. Cash and cash equivalents, consist of bank deposits or highly liquid investment-grade debt instruments with an original maturity of three months or less when purchased pursuant to the Company’s investment policy. The Company maintains several bank accounts for its operations primarily at three financial institutions in the U.S. and one financial institution in Hong Kong. The Company’s U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 at each institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company’s trade receivables are derived from sales to its customers. The Company assesses credit risk of its customers through quantitative and qualitative analysis. From this analysis, the Company establishes credit limits and manages the risk exposure. The Company, however, may from time-to-time incur credit losses due to bankruptcy or other failures from its customers to pay.</span>
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67185000 shares
CY2022 cdxc Straight Line Method
StraightLineMethod
P10Y
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16500000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15100000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20300000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16540000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69729000 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69729000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67185000 shares
CY2022 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
650000 shares
CY2021 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
115000 shares
CY2022 cdxc Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
CY2021 cdxc Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2022 us-gaap Revenues
Revenues
72050000 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
29253000 usd
CY2022 us-gaap Gross Profit
GrossProfit
42797000 usd
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28313000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4826000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28286000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
61425000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-18628000 usd
CY2021 us-gaap Revenues
Revenues
67449000 usd
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
25959000 usd
CY2021 us-gaap Gross Profit
GrossProfit
41490000 usd
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28352000 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3832000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36379000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
68563000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-27073000 usd
CY2022 us-gaap Revenues
Revenues
72050000 usd
CY2021 us-gaap Revenues
Revenues
67449000 usd
CY2022 us-gaap Proceeds From Customers
ProceedsFromCustomers
21800000 usd
CY2021 us-gaap Proceeds From Customers
ProceedsFromCustomers
19800000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7901000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6823000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2992000 usd
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4131000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3284000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2131000 usd
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
500000 usd
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
516000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
14677000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
13601000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2318000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2132000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
671000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
857000 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
186000 usd
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
225000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
4554000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
158000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
154000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
151000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
151000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
42000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
15000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
671000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
7353000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
7547000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
4544000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2799000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3003000 usd
CY2022 us-gaap Depreciation
Depreciation
869000 usd
CY2021 us-gaap Depreciation
Depreciation
890000 usd
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3500000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4400000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4200000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4700000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
941000 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
625000 usd
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
176000 usd
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
195000 usd
CY2022 cdxc Total Operating Lease Expenses
TotalOperatingLeaseExpenses
1117000 usd
CY2021 cdxc Total Operating Lease Expenses
TotalOperatingLeaseExpenses
820000 usd
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
164000 usd
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
249000 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1281000 usd
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1069000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
843000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1101000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1135000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
901000 usd
CY2022 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
77000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
491000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
387000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4858000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
639000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4219000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
680000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3539000 usd
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.764
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.746
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Price
SharePrice
1.68
CY2022Q4 us-gaap Share Price
SharePrice
1.68
CY2022Q4 us-gaap Share Price
SharePrice
1.68
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5739000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6195000 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5400000 usd
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
69000 usd
CY2022 cdxc Supply Commitment Milestone Payment
SupplyCommitmentMilestonePayment
0 usd
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
391000 usd
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
432000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3955000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4346000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.055
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.032
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.018
CY2022 cdxc Change In State Tax Rate
ChangeInStateTaxRate
-0.003
CY2021 cdxc Change In State Tax Rate
ChangeInStateTaxRate
0.001
CY2022 cdxc Effective Income Tax Rate Reconciliation Tax Expirations Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationTaxExpirationsOfNetOperatingLosses
0.016
CY2021 cdxc Effective Income Tax Rate Reconciliation Tax Expirations Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationTaxExpirationsOfNetOperatingLosses
-0.028
CY2022 cdxc Effective Income Tax Rate Reconciliation Tax Change In Stock Options And Restricted Stock
EffectiveIncomeTaxRateReconciliationTaxChangeInStockOptionsAndRestrictedStock
-0.078
CY2021 cdxc Effective Income Tax Rate Reconciliation Tax Change In Stock Options And Restricted Stock
EffectiveIncomeTaxRateReconciliationTaxChangeInStockOptionsAndRestrictedStock
0.049
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.177
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.298
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37308000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36136000 usd
CY2022Q4 cdxc Deferred Tax Assets Stock Options And Restricted Stock
DeferredTaxAssetsStockOptionsAndRestrictedStock
4528000 usd
CY2021Q4 cdxc Deferred Tax Assets Stock Options And Restricted Stock
DeferredTaxAssetsStockOptionsAndRestrictedStock
4805000 usd
CY2022Q4 cdxc Deferred Tax Assets Tax Interest Expense
DeferredTaxAssetsTaxInterestExpense
258000 usd
CY2021Q4 cdxc Deferred Tax Assets Tax Interest Expense
DeferredTaxAssetsTaxInterestExpense
244000 usd
CY2022Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
410000 usd
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
399000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
32000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
17000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1654000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1073000 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
922000 usd
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1050000 usd
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
880000 usd
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
60000 usd
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
74000 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
104000 usd
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
95000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
185000 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
85000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46511000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43808000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46254000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43363000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
257000 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
445000 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
257000 usd
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
445000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
257000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
445000 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2900000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
46200000 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43300000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Gilti Amount
EffectiveIncomeTaxRateReconciliationGiltiAmount
0 usd
CY2022Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
18000000 usd
CY2022Q4 us-gaap Purchase Obligation
PurchaseObligation
18000000 usd
CY2022 us-gaap Royalty Expense
RoyaltyExpense
2000000 usd
CY2021 us-gaap Royalty Expense
RoyaltyExpense
1800000 usd
CY2019Q3 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
1600000 usd
CY2022Q3 cdxc Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2100000 usd
CY2022Q4 cdxc Proceeds From Employee Retention Tax Credit Cares Act
ProceedsFromEmployeeRetentionTaxCreditCARESAct
600000 usd
CY2022Q4 cdxc Prepaid Expenses And Other Current Assets Employee Retention Credit Cares Act
PrepaidExpensesAndOtherCurrentAssetsEmployeeRetentionCreditCARESAct
1800000 usd
CY2022Q4 cdxc Accrued Expenses Employee Retention Credit Cares Act
AccruedExpensesEmployeeRetentionCreditCARESAct
300000 usd

Files In Submission

Name View Source Status
0001628280-23-006968-index-headers.html Edgar Link pending
0001628280-23-006968-index.html Edgar Link pending
0001628280-23-006968.txt Edgar Link pending
0001628280-23-006968-xbrl.zip Edgar Link pending
cdxc-20221231.htm Edgar Link pending
cdxc-20221231_pre.xml Edgar Link unprocessable
cdxc-20221231_cal.xml Edgar Link unprocessable
cdxc-20221231.xsd Edgar Link pending
cdxc-20221231_g1.jpg Edgar Link pending
cdxc-20221231_g2.jpg Edgar Link pending
cdxc-20221231_g3.jpg Edgar Link pending
cdxc8thamendmenttomanufact.htm Edgar Link pending
cdxcq4202210kex231consent.htm Edgar Link pending
cdxcq4202210kexhibit311.htm Edgar Link pending
cdxcq4202210kexhibit312.htm Edgar Link pending
cdxcq4202210kexhibit321.htm Edgar Link pending
cdxcq42022ex211subsidiaries.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
cdxc-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cdxc-20221231_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
waiverof2022bonuscompensat.htm Edgar Link pending
cdxc-20221231_def.xml Edgar Link unprocessable